PAA 2.56% 20.0¢ pharmaust limited

Ann: Additional Phase 1 data suggest MPL may inhibit MND, page-380

  1. 8,846 Posts.
    lightbulb Created with Sketch. 1712
    PAA do have a business plan which has been communicated quite a few times maybe not called a business plan, the last time it was listed was in quarterly issued 29 April 2022 and listed as activity timelines in that announcement.
    The main problems have been the inability of the board to deliver to the plan / timelines and the fact that shareholders have not held the board to account.
    So what did the activity timeline state
    MND trial completed 21 October 2022
    Start of human cancer trial December 2022
    End of canine trial in 2022


    Now as for the reward oppies I guess the plan may have been for the expectation that long term holders could sell the oppies, which they could have and made a 40 to 50% profit so really I guess holders took the risk in hope of a greater return so we really can not blame the company if the oppies do not get in the money
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.